Single Buffer Nucleic Acid Purification Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid purification methods are laborious and time-consuming due to multiple washing steps and the need for different buffers during the binding, washing, and elution processes, which can interfere with downstream procedures.
Innovation Solution
A method utilizing a single buffer solution with low salt concentration (≤100 mM) and high pH (≥7.5) for both washing and eluting nucleic acids bound to a binding phase, simplifying the process and allowing for efficient purification in miniaturized environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If multiple washing steps with different buffers are used, then purification quality is improved, but processing time and operational complexity increase
Solution Approach 1:
The patent combines multiple washing steps with different buffers into a single washing step using one buffer solution that contains both chaotropic salt and alcohol. This merging approach maintains the purification quality that would otherwise require multiple sequential washing steps with different buffer compositions, thereby reducing processing time and simplifying the overall nucleic acid purification process.
Solution Approach 2:
The single buffer solution developed in the patent serves multiple functions simultaneously: it acts as both a washing buffer and an elution buffer. The buffer contains chaotropic salt for maintaining nucleic acid binding during washing, alcohol for removing impurities, and appropriate pH for subsequent elution. This multi-functionality eliminates the need for separate washing and elution buffers, reducing both processing time and buffer preparation complexity.
2Productivity
If multiple different buffers are used for washing and elution, then binding and washing efficiency is improved, but the number of reagents and procedural steps increases
Solution Approach 1:
The patent merges the functions of multiple washing buffers into a single buffer solution that contains chaotropic salt, alcohol, and appropriate buffering agents. This single buffer performs the washing function that would otherwise require multiple different buffers with different compositions, thereby reducing the number of reagents needed while maintaining binding and washing efficiency.
Solution Approach 2:
The developed buffer solution is designed to be universal, serving both as a washing buffer and an elution buffer. It contains chaotropic salt to maintain nucleic acid binding during washing, alcohol to remove impurities, and pH control to enable subsequent elution. This universality reduces the number of procedural steps and reagents from multiple separate buffers to a single multi-functional buffer.
3Productivity
If traditional washing buffers are used, then washing capacity is improved, but buffer remains difficult to remove and interferes with downstream procedures
Solution Approach 1:
The patent changes the composition parameters of the washing buffer by incorporating alcohol and optimizing the chaotropic salt concentration. These parameter changes enable the buffer to be effectively removed during the washing process while maintaining its washing capacity. The alcohol component facilitates easier removal of the buffer solution, preventing interference with downstream procedures such as PCR analysis or sequencing reactions.
Solution Approach 2:
The buffer solution is designed with local quality optimization where different components serve specific functions: chaotropic salt for maintaining binding, alcohol for removing impurities and facilitating buffer removal, and buffering agents for pH control. This localized functional assignment within the single buffer ensures high washing capacity while minimizing residual buffer interference with downstream applications.
4Volume of moving object
If miniaturized purification is implemented, then sample volume is reduced, but elution efficiency decreases with small volumes
Solution Approach 1:
The patent optimizes the buffer composition parameters specifically for miniaturized applications. By adjusting the concentrations of chaotropic salt, alcohol, and buffering agents, the buffer maintains high elution efficiency even in small volumes. The optimized composition ensures that the buffer can effectively compete with the binding phase for nucleic acid binding, enabling high elution efficiency in miniaturized formats such as microfluidic devices or small-scale purification protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces processing time, minimizes interference with downstream analyses, and enables high elution efficiency using small volumes, making the method more economical and reproducible, suitable for miniaturized environments like microfluidic devices.
Implementation Method 1
eluting the nucleic acids from the nucleic acid binding phase using the buffer solution of step (ii)
Implementation Method 2
binding and washing negatively charged nucleic acids on a nucleic acid binding phase, which is positively charged when immersed in buffer solution
Data Source
AI summary
A simplified method of obtaining purified nucleic acids uses a single buffer solution to both wash and elute nucleic acids bound to a binding phase. Use of a single buffer solution avoids the time-consuming aspect of using different wash and elution buffer solutions during multiple nucleic acid purification steps. The method for purifying nucleic acids using a single buffer solution includes steps of:exposing a sample comprising nucleic acids to a nucleic acid binding phase, where the nucleic acid binding phase may include magnetic particles, silica particles, or a mixture thereof; and allowing the nucleic acids to bind to the nucleic acid binding phase;washing the nucleic acids bound to the nucleic acid binding phase at least once with the single buffer solution at room temperature; andeluting the nucleic acids from the nucleic acid binding phase with ≤50 μl of the single buffer solution, at a temperature of ≥40° Celsius.